Celestone + placebo
DrugAfter the first intramuscular injection of Celestone, participants randomized to the "Placebo Comparator" group will receive 1 intramuscular injection of placebo.
NCT Number: NCT05114096
Antenatal corticosteroids (ACS) reduce the risks of neonatal death and morbidities in preterm infants, such as respiratory distress syndrome.
The standard of care for pregnant people at risk of preterm birth includes 2 doses of Celestone (for a total of 24 mg in Canada, or 22.8 mg in Australia) to accelerate fetal lung maturity.
The investigators plan to conduct a randomized controlled trial to determine whether half the usual dose (12 mg in Canada, or 11.4 mg in Australia) of Celestone is non-inferior to the standard double doses.
Interested in participating?
Request Info18 year–55 year
Female
Interventional
Phase 4
University of Calgary, Cumming School of Medicine, Calgary, Alberta, Canada
Preterm infants are at risk of mortality and morbidity. Antenatal corticosteroids (ACS) reduce the risks of neonatal death and morbidities, such as respiratory distress syndrome.
The standard of care for pregnant people at risk of preterm birth includes 2 doses of Celestone to accelerate fetal lung maturity (total 24 mg in Canada, 22.8 mg in Australia). There are no published clinical trial data on the benefits or risks of a single dose of antenatal corticosteroid vs. standard double doses (Ninan et al JOGC 2020).
Pregnant people at 22 weeks and 0 days to < 34 weeks and 6 days' gestation at risk of preterm birth with a singleton or twin gestation who have received the first dose of Celestone and consented to the trial will be randomized to receive approximately 24 hours later either an experimental placebo injection (of normal saline) or the standard double dose of Celestone to determine whether the intervention is non-inferior for the primary outcome of a composite of perinatal mortality or substantial morbidity.
Please note: Based on Health Canada's' guidance the study phase is 'Other: Off-Label use'. However, on the clincaltrial.gov record, 'Phase 4' is selected as this is the most relevant phase and there is no option to select 'Other'.
Please note: McMaster University, Canada is the Canadian Regulatory Sponsor and Overall Sponsor, and the University of Adelaide Australia is the Australian Sponsor.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
After the first intramuscular injection of Celestone, participants randomized to the "Placebo Comparator" group will receive 1 intramuscular injection of placebo.
After the first intramuscular injection of Celestone, participants randomized to the "Active Comparator" group will receive 1 intramuscular injection of Celestone.
Time frame: approximately 1 month
Fetal death post-randomization or in hospital neonatal death OR => 1 of respiratory morbidity (requiring surfactant <=48 hrs of life), severe intraventricular hemorrhage (distending/beyond the ventricles, i.e. Grade 3 or 4), or severe bowel problem (necrotizing enterocolitis, Stage 2 or 3)
Time frame: approximately 24 months
Death or neurosensory/developmental impairment at 24 months (+/- 6 months; accounting for gestation at birth), mood (anxiety/depression), behavior (aggression), etc as assessed by:
Time frame: approximately up to first 6 months of life
Number of babies who received intubation and duration of invasive mechanical ventilation
Time frame: approximately up to first 6 months of life
Number of babies who received, and duration of, supplemental oxygen (after resuscitation) and other ventilatory support
Time frame: approximately 1 month
Number of babies with respiratory distress after the initial resuscitation/stabilization and main cause (such as respiratory distress syndrome, pneumothorax/pneumomediastinum, pneumonia, transient tachypnea of the newborn, meconium aspiration syndrome, persistent pulmonary hypertension of the newborn)
Time frame: approximately at birth
Respiratory distress after the initial resuscitation/stabilization and main cause (such as respiratory distress syndrome, pneumothorax/pneumomediastinum, pneumonia, transient tachypnea of the newborn, meconium aspiration syndrome, persistent pulmonary hypertension of the newborn),
Time frame: 48 hours
Number of babies with hypoglycemia (low plasma glucose < 2.6 mmol/L between 30 minutes and 48 hours of life)
Time frame: 7 days
Number of babies with neonatal sepsis within 7 days of birth, defined as a positive (bacterial, viral or fungal): blood culture or cerebrospinal fluid culture (or gram stain) or urine culture by sterile collection.
Time frame: approximately first few months of life
Number of babies with severe retinopathy of prematurity defined as requiring vascular endothelial growth factor (VEGF) or laser or cryotherapy per the local guidelines
Time frame: up to 12 weeks after birth
Number of babies with patent ductus arteriosus (PDA) needing a closure procedure (surgery or device)
Time frame: at birth and at 24 months corrected age
Weight (in grams), length (in centimeters), and head circumference (in centimeters) for birth week as ACS can impact growth
Time frame: up to 20 weeks postnatal
Periventricular leukomalacia [PVL], i.e. cystic changes in white matter or porencephalic cysts or white matter changes diagnosed by ultrasound or MRI.
Time frame: approximately up to first 6 months of life
Late respiratory morbidity, bronchopulmonary dysplasia (BPD), defined as requiring respiratory support or supplemental oxygen > 36 completed weeks' corrected gestation.
Time frame: approximately at birth
Apgar score (at 1 and 5 min) and lowest cord blood pH, regardless of whether arterial or venous.
Time frame: approximately up to first 6 months of life
Length of stay in an intensive care setting such as the neonatal intensive care unit (NICU).
Time frame: up to 20 weeks postnatal
Use of systemic (intravenous or oral) postnatal corticosteroids and type (e.g. hydrocortisone, dexamethasone).
Time frame: approximately 5 -10 years
Number of babies with reported longterm health care outcomes after initial hospital, such as hospitalizations, and other health care use.
Time frame: approximately 5 -10 years
Number of babies with reported longterm education or non-health data outcomes, collected through database linkage where possible.
Time frame: approximately 1 month
Fetal death post-randomization or in hospital neonatal death OR => 1 of respiratory morbidity (requiring surfactant <=48 hrs of life), severe intraventricular hemorrhage (distending/beyond the ventricles, i.e. Grade 3 or 4), or severe bowel problem (necrotizing enterocolitis, Stage 2 or 3)
Contact information is provided by the study sponsor or research team.
McMaster University
Other
Single Dose of Antenatal Corticosteroids (SNACS) Randomized Controlled Trial for Pregnancies at Risk of Preterm Delivery: To Keep Babies and Children Safe
Acronym: SNACS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07577388
Abortion, Habitual, Abortion, Spontaneous
View Trial DetailsNCT04494529
Complication of Prematurity, Female Urogenital Diseases and Pregnancy Complications
Hamilton, Ontario, Canada
View Trial DetailsNCT03154177
Death, Female Urogenital Diseases and Pregnancy Complications
Kigali, Rwanda
View Trial DetailsNCT03112018
Death, Female Urogenital Diseases and Pregnancy Complications
Migori County, Kenya
View Trial Details